Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tyra Biosciences Inc (TYRA)

Tyra Biosciences Inc (TYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,180,055
  • Shares Outstanding, K 53,372
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,480 K
  • EBIT $ -126 M
  • EBITDA $ -125 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.12

Options Overview Details

View History
  • Implied Volatility 143.52% (+27.11%)
  • Historical Volatility 78.50%
  • IV Percentile 30%
  • IV Rank 30.71%
  • IV High 357.21% on 09/12/25
  • IV Low 48.81% on 09/09/25
  • Expected Move (DTE 14) 2.81 (13.05%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 481
  • Open Int (30-Day) 443
  • Expected Range 18.70 to 24.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.54
  • Number of Estimates 7
  • High Estimate -0.50
  • Low Estimate -0.63
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -25.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.35 +61.05%
on 11/06/25
22.83 -5.81%
on 11/28/25
+6.68 (+45.07%)
since 11/05/25
3-Month
11.70 +83.72%
on 09/11/25
22.83 -5.81%
on 11/28/25
+8.85 (+69.96%)
since 09/05/25
52-Week
6.42 +234.89%
on 04/09/25
22.83 -5.81%
on 11/28/25
+6.33 (+41.73%)
since 12/05/24

Most Recent Stories

More News
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 21.50 (-2.76%)
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 14.89 (-3.00%)
TYRA : 21.50 (-2.76%)
DMAC : 8.78 (+1.74%)
XBI : 123.41 (+0.13%)
Tyra Biosciences Announces Participation at Upcoming Investor Events

CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 21.50 (-2.76%)
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -

TYRA : 21.50 (-2.76%)
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-

TYRA : 21.50 (-2.76%)
Tyra Biosciences Announces Participation at Upcoming Investor Events

CARLSBAD, Calif. , Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines...

TYRA : 21.50 (-2.76%)
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -

TYRA : 21.50 (-2.76%)
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

CARLSBAD, Calif. , July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines...

TYRA : 21.50 (-2.76%)
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted expert predictions...

ONCY : 0.9921 (+1.16%)
TYRA : 21.50 (-2.76%)
ZNTL : 1.3900 (-0.71%)
ONC.TO : 1.42 (+2.16%)
CMPX : 5.53 (-0.18%)
CCCC : 2.67 (+3.09%)
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...

TYRA : 21.50 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 23.66
2nd Resistance Point 23.20
1st Resistance Point 22.35
Last Price 21.50
1st Support Level 21.04
2nd Support Level 20.58
3rd Support Level 19.73

See More

52-Week High 22.83
Last Price 21.50
Fibonacci 61.8% 16.56
Fibonacci 50% 14.62
Fibonacci 38.2% 12.69
52-Week Low 6.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar